泛昔洛韦和α-干扰素联合治疗慢性乙型肝炎疗效观察  

Clinical efficacy of Famciclovir combined with Interferon -α on Chronic Hepatitis B

作　　者：邵凤娟[1] 王菲[1] 于丹萍[1] 

机构地区：[1]哈尔滨医科大学附属一院传染科,黑龙江哈尔滨150001

出　　处：《临床肝胆病杂志》2002年第1期45-46,共2页Journal of Clinical Hepatology

摘　　要：为探讨泛昔洛韦和α－干扰素联合治疗慢性乙型肝炎的疗效，选择４２例慢性乙型肝炎患者，随机分为两组，Ａ组 １８例应用泛昔洛韦和α－干扰素联合治疗 ； Ｂ组 ２４例单用 α－干扰素治疗。治疗前后分别检测肝功、乙肝六项和 ＨＢＶ－ＤＮＡ治疗结束时，Ａ组ＡＬＴ复常率为 ８３．３ ％、ＨＧｅＡｇ阴转率为 ７６．４％．ＨＢＶ－ＤＮＡ阴转率为７７．８％；而 Ｂ组分别为 ７５．０％，３８．１％和 ４１．７％． 两组间 ＨＧｅＡｇ阴转率和 ＨＢＶ－ＤＮＡ阴转率有显著差异。泛昔洛韦和α－干扰素联合治疗慢性乙型肝炎疗效更佳。To explore the efficacy of Famciclovir combined with Interferon -α on chronic hepatitis B. 42 cases with chrome hepatitis B were randomly divided in to two groups. Group A was given Famciclovir combined with IFN -α. Group B was given IFN -α only. The value of ALT, serologic markers of HBV and HBV - DNA were detected respectively before and after treatment. At the end of treatment, the ALT normalization rate, the HBeAg seroconversion rate and the HBV -DNA Seroconversion rate of group A were 83. 3%. 76. 4% and 77. 8%. respectively. These of group B were 75. 0%.38.1 % and 41. 7%, respectively. There were significantly difference in the HBeAg and the HBV - DNA Seroconversion rate between group A and group B. Famciclovir combined with IFN -α on chronic hepatitis B is more effective.

关 键 词：慢性乙型肝炎 泛昔洛韦 Α-干扰素 临床疗效 

分 类 号：R512.62[医药卫生—内科学] R978.7[医药卫生—临床医学]